Sort   by:  
 Page size 
ProteomicsA dataset describing a suite of novel antibody reagents for the RAS signaling network
RAS genes are frequently mutated in cancer and have for decades eluded effective therapeutic attack. The National Cancer Institute’s RAS Initiative has a focus on understanding pathways and discovering therapies for RAS-driven cancers. Part of these efforts is the generation of novel reagents to ena...
ORGANISM(S): Homo Sapiens 
2019-09-03 | PXD012604 | panorama
UnknownResults of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Not available
S-EPMC3646316 | biostudies-literature
GenomicPancreatic Cancer Cohort and Case-Control Consortium (PanScan)

Within the framework of the NCI-sponsored Cohort Consortium, investigators from 12 prospective epidemiologic cohorts formed the Pancreatic Cancer Cohort Consortium in 2006. This study, also known as "PanScan", is funded by the National Cancer Institute (NCI) and involves conducting a geno...

phs000206 | dbGaP
GenomicsWomen's Health Initiative Clinical Trial and Observational Study

The Women's Health Initiative (WHI) is a long-term national health study that has focused on strategies for preventing heart disease, breast and colorectal cancer, and osteoporotic fractures in postmenopausal women. The original WHI study included 161,808 postmenopausal women enrolled between...

phs000200.v7.p2 | EGA
GenomicsWhole Genome Scan for Pancreatic Cancer Risk in the Pancreatic Cancer Cohort Consortium and Pancreatic Cancer Case-Control Consortium (PanScan)

Within the framework of the NCI-sponsored Cohort Consortium, investigators from 12 prospective epidemiologic cohorts formed the Pancreatic Cancer Cohort Consortium in 2006. This study, also known as "PanScan", is funded by the National Cancer Institute (NCI) and involves conducting a genome-w...

phs000206.v3.p2 | EGA
ProteomicsTargeted mass spectrometry enables multiplexed quantification of immunomodulatory proteins in clinical biospecimens
Immunotherapies are revolutionizing cancer care, producing durable responses and potentially cures in a subset of patients. However, response rates are low for most tumors, grade 3/4 toxicities are not uncommon, and our current understanding of tumor immunobiology is incomplete. While hundreds of im...
ORGANISM(S): Homo Sapiens 
2022-02-28 | PXD029167 | panorama
UnknownOutcomes of COVID-19 in patients with CLL: a multicenter international experience.
Not available
S-EPMC7472711 | biostudies-literature
UnknownSociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.
Not available
S-EPMC7745688 | biostudies-literature
UnknownCOVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
Not available
S-EPMC8313815 | biostudies-literature
Sort   by:  
 Page size